Ademi LLP is investigating Nuvalent's $10.6 billion sale to GSK, alleging possible breaches of fiduciary duty by Nuvalent's board. The deal offers Nuvalent shareholders $124 per share, but insiders stand to gain extra benefits. The transaction also includes restrictions that penalize competing bids, raising concerns about fairness. The investigation focuses on whether the board acted in shareholders' best interests during the sale process.
Halper Sadeh LLC is investigating the sales of Avanos Medical, Nuvalent, XOMA Royalty, and TruBridge for possible breaches of federal securities laws and fiduciary duties to shareholders. The firm suggests insiders may gain financial benefits not ava...
Halper Sadeh LLC is investigating whether shareholders of Nuvalent, SUNation Energy, Organon & Co., and Taylor Morrison Home Corporation are receiving fair treatment in their companies' recent sales or mergers. The law firm highlights potential confl...
GSK has agreed to acquire Boston-based biotech firm Nuvalent for $10.6 billion in cash, paying $124 per share, a 40% premium over the last closing price. This marks GSK's largest acquisition in over a decade and aims to strengthen its lung cancer dru...
Monteverde & Associates PC is investigating the sale of Nuvalent, Inc. to GSK plc, where Nuvalent shareholders are set to receive $124 per share in cash. The investigation questions whether this deal is fair to shareholders. The law firm, known for r...
British pharmaceutical company GSK announced it will acquire cancer drug developer Nuvalent for $10.6 billion. This deal caused Nuvalent's stock to surge 39% as investors reacted positively to the acquisition. The move highlights GSK's strategic inve...
